Development of cell-cycle inhibitors for cancer therapy

Yazar: Dickson, M.A., Schwartz, G.K.
Baskı/Yayın Bilgisi 2009

Sarcoma Immunotherapy: Past Approaches and Future Directions

Yazar: D'Angelo, S. P., Tap, W. D., Schwartz, G. K., Carvajal, R. D.
Baskı/Yayın Bilgisi 2014

Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”

Yazar: D'Angelo, S. P., Tap, W. D., Schwartz, G. K., Carvajal, R. D.
Yayımlandı Sarcoma (2015)

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

Yazar: Schwartz, G K, LoRusso, P M, Dickson, M A, Randolph, S S, Shaik, M N, Wilner, K D, Courtney, R, O'Dwyer, P J
Baskı/Yayın Bilgisi 2011

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

Yazar: Dickson, M. A., Okuno, S. H., Keohan, M. L., Maki, R. G., D'Adamo, D. R., Akhurst, T. J., Antonescu, C. R., Schwartz, G. K.
Baskı/Yayın Bilgisi 2013

FLT-PET at 6 weeks predicts response assessed by CT at 12 weeks in melanoma patients treated with pembrolizumab

Yazar: Yeh, R., Trager, M.H., Rizk, E.M., Finkel, G., Barker, L., Carvajal, R.D., Geskin, L.J., Schwartz, G.K., Schwartz, L., Dercle, L., Saenger, Y.M.
Yayımlandı Clin Nucl Med (2020)

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma(†)

Yazar: Dickson, M. A., Mahoney, M. R., Tap, W. D., D'Angelo, S. P., Keohan, M. L., Van Tine, B. A., Agulnik, M., Horvath, L. E., Nair, J. S., Schwartz, G. K.
Yayımlandı Ann Oncol (2016)

High-risk features in radiation-associated breast angiosarcomas

Yazar: D'Angelo, S P, Antonescu, C R, Kuk, D, Qin, L, Moraco, N, Carvajal, R C, Chi, P, Dickson, M A, Gounder, M, Keohan, M L, Singer, S, Schwartz, G K, Tap, W D
Baskı/Yayın Bilgisi 2013

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules...

Yazar: Boss, D. S., Schwartz, G. K., Middleton, M. R., Amakye, D. D., Swaisland, H., Midgley, R. S., Ranson, M., Danson, S., Calvert, H., Plummer, R., Morris, C., Carvajal, R. D., Chirieac, L. R., Schellens, J. H. M., Shapiro, G. I.
Baskı/Yayın Bilgisi 2010

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Yazar: Grivas, P., Khaki, A.R., Wise-Draper, T.M., French, B., Hennessy, C., Hsu, C.-Y., Shyr, Y., Li, X., Choueiri, T.K., Painter, C.A., Peters, S., Rini, B.I., Thompson, M.A., Mishra, S., Rivera, D.R., Acoba, J.D., Abidi, M.Z., Bakouny, Z., Bashir, B., Bekaii-Saab, T., Berg, S., Bernicker, E.H., Bilen, M.A., Bindal, P., Bishnoi, R., Bouganim, N., Bowles, D.W., Cabal, A., Caimi, P.F., Chism, D.D., Crowell, J., Curran, C., Desai, A., Dixon, B., Doroshow, D.B., Durbin, E.B., Elkrief, A., Farmakiotis, D., Fazio, A., Fecher, L.A., Flora, D.B., Friese, C.R., Fu, J., Gadgeel, S.M., Galsky, M.D., Gill, D.M., Glover, M.J., Goyal, S., Grover, P., Gulati, S., Gupta, S., Halabi, S., Halfdanarson, T.R., Halmos, B., Hausrath, D.J., Hawley, J.E., Hsu, E., Huynh-Le, M., Hwang, C., Jani, C., Jayaraj, A., Johnson, D.B., Kasi, A., Khan, H., Koshkin, V.S., Kuderer, N.M., Kwon, D.H., Lammers, P.E., Li, A., Loaiza-Bonilla, A., Low, C.A., Lustberg, M.B., Lyman, G.H., McKay, R.R., McNair, C., Menon, H., Mesa, R.A., Mico, V., Mundt, D., Nagaraj, G., Nakasone, E.S., Nakayama, J., Nizam, A., Nock, N.L., Park, C., Patel, J.M., Patel, K.G., Peddi, P., Pennell, N.A., Piper-Vallillo, A.J., Puc, M., Ravindranathan, D., Reeves, M.E., Reuben, D.Y., Rosenstein, L., Rosovsky, R.P., Rubinstein, S.M., Salazar, M., Schmidt, A.L., Schwartz, G.K., Shah, M.R., Shah, S.A., Shah, C., Shaya, J.A., Singh, S.R.K., Smits, M., Stockerl-Goldstein, K.E., Stover, D.G., Streckfuss, M., Subbiah, S., Tachiki, L., Tadesse, E., Thakkar, A., Tucker, M.D., Verma, A.K., Vinh, D.C., Weiss, M., Wu, J.T., Wulff-Burchfield, E., Xie, Z., Yu, P.P., Zhang, T., Zhou, A.Y., Zhu, H., Zubiri, L., Shah, D.P., Warner, J.L., Lopes, GdL.
Yayımlandı Ann Oncol (2021)